The Drug Supply Chain Security Act of 2013 calls for the development of an electronic, interoperable system by 2023 to track prescription drugs as they are distributed across the supply chain. The law also requires drug distributors to notify the agency of any illegitimate drug products within 24 hours. The law also places product tracing requirements on certain supply chain stakeholders like repackagers, wholesale drug distributors and third-party logistics providers.
The draft guidance seeks to clarify what provisions apply to which entities in accordance with the DSCSA.
The FDA will hold the first of three public meetings on the topic Thursday.
To view the draft guidance, click here.
More articles on supply chain:
Survey: 66% of Californians oppose drug price transparency bill
Samsung widens stake in prescription drug market through partnership with Japanese pharmaceutical company
Patients brace for price of ‘breakthrough’ leukemia drug CTL019
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
